We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Tuesday that the European Medicines Agency has accepted a variation to its marketing-authorization application for Tagrisso, for treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer.
The pharmaceutical company said the drug application, which is an epidermal growth factor receptor inhibitor, was based on data from the phase 3 trial, in which Tagrisso significantly improved progression-free survival compared to current treatments.
On Monday, AstraZeneca reported the submission of a supplemental new drug application to Japan's Pharmaceuticals and Medical Devices Agency for the use of Tagrisso.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
November 28, 2017 02:30 ET (07:30 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
